Complications of intravesical bacillus Calmette-Guerin: a case report.
Bacillus Calmette-Guerin (BCG) is the most effective agent currently available to treat superficial bladder cancer. However, this form of therapy is not without potential serious or fatal complications. In addition to the potentially toxic systemic side effects attributed to hematogenous absorption of the bacillus, direct upper tract seeding may occur in patients with vesicoureteral reflux. We report on a patient treated with intravesical BCG for bladder cancer in whom unilateral necrotizing granulomatous pyelonephritis developed. Although severe, this complication is rare and we conclude that reflux is not a contraindication for intravesical BCG therapy.
Gonzalez
J A
JA
Department of Urology, William Beaumont Hospital, Royal Oak, Michigan.
Marcol
B R
BR
Wolf
M C
MC
D000283:Administration, Intravesical; D000368:Aged; D001500:BCG Vaccine / Q000009:adverse effects* / Q000627:therapeutic use; D002278:Carcinoma in Situ / Q000628:therapy*; D006801:Humans; D007681:Kidney Papillary Necrosis / Q000209:etiology*; D008297:Male; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D001500:BCG Vaccine